The molecular mechanism governing the ability of SNAI1 and SEMA4A in PBMCs to safeguard the initiation or progression of breast cancer needs to be studied in further detail to determine methods to tap this defensive mechanism in treating cancer patients. This evidence concerns the gene SEMA4A and breast carcinoma.